Brussels, Belgium-headquartered UCB Group is highlighting the potential role of its dual interleukin-17A and -17F inhibiting MAb, bimekizumab, for the treatment of hidradenitis suppurativa. The disease has a high unmet need and a Phase III trial of bimekizumab in the condition has just started, the company says.
UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline
Painful Skin Abscesses, Myasthenia Gravis And Refractory Epilepsy Targeted
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
More from Immunological
• By
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
• By
J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.